U.S. markets close in 11 minutes

Evogene Ltd. (EVGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.5700+0.1800 (+4.10%)
As of 3:48PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.3900
Open4.8535
Bid4.5900 x 1400
Ask4.6100 x 800
Day's Range4.4215 - 4.9500
52 Week Range0.9000 - 10.2400
Volume1,764,633
Avg. Volume1,560,681
Market Cap187.349M
Beta (5Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.8300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma
    PR Newswire

    Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma

    Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced additional positive pre-clinical results in its immuno-oncology program demonstrating efficacy of its live biotherapeutic product (LBP) consortium BMC128, this time in melanoma. In these studies, Biomica tested BMC128, which consists of four live bacterial strains, in a mouse model of melanoma.

  • Evogene to Hold Virtual Investor & Analyst Days
    PR Newswire

    Evogene to Hold Virtual Investor & Analyst Days

    Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company today announced that it will hold virtual investor and analyst days, in both Hebrew and English, via Zoom webinars.

  • Evogene Files Annual Report for the Year Ended December 31, 2020
    PR Newswire

    Evogene Files Annual Report for the Year Ended December 31, 2020

    Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the "SEC").